Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported September 27, Aytu BioPharma Q4 EPS $(0.59) Beats $(0.95) Estimate, Sales $30.73M Beat $27.69M Estimate

Author: Happy Mohamed | September 28, 2023 11:47am
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.95) by 37.89 percent. This is a 93.98 percent increase over losses of $(9.80) per share from the same period last year. The company reported quarterly sales of $30.73 million which beat the analyst consensus estimate of $27.69 million by 10.99 percent. This is a 11.96 percent increase over sales of $27.45 million the same period last year.

Posted In: AYTU


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist